Sample to Answer in 30 Minutes

Xzōm’s breakthrough technology provides unprecedented access to exosomal analysis, enabling superior diagnostics and earlier disease detection.

Life-Threatening Diseases Require Rapid Results

Sending diagnostic samples to large reference laboratories for testing can leave patients waiting for days or weeks for answers.

This process is not fast enough.

Xzōm is providing near-patient diagnostic solutions, powered by their proprietary Alternating Current Electrokinetics (ACE) technology, that enable the isolation, analysis, and quantification of exosome biomarkers for early disease detection on a single platform from a minimal blood sample—with results in less than 30 minutes.

< 80 μL

Low Sample Volumes

30 Minutes

Rapid Results

1 Platform

Easy-to-Use Instrument

A Simple Workflow that Delivers Rapid Results

Xzōm’s easy-to-use, near-patient platform delivers rapid, high performance diagnostic results from small sample volumes.

30 Minutes

Novel Technology Built On A Strong Foundation

Early Disease Detection Powered by ACE Technology

At Xzōm, we utilize our patented Alternating Current Electrokinetics (ACE) technology to rapidly isolate exosomes, proteins, cell-free DNA, and other extracellular vesicles from a minimal blood sample.

A Simple 3-Step Process

1. Load Sample

2. Activate ACE

3. Fluidic Wash

Exosomes: Cellular Messengers

Cells have a story to tell and exosomes are their messengers. Exosomes contain wide range of biomolecules – DNA, RNA, amino acids, proteins, and metabolites – that can indicate the onset of disease.

Exosomes arise from all cell types and are continuously secreted into all biological fluids—blood, saliva, urine, breast milk, amniotic fluid, cerebrospinal fluid, and they even cross the blood-brain-barrier—providing unlimited opportunities for biomarker analysis, early disease detection, and longitudinal monitoring of patient health.

Learn how we are leveraging exosomal data to detect multiple conditions.

Placeholder Title Placeholder Title

Placeholder Title

Placeholder Title

Placeholder Title

Novel Technology Built On A Strong Foundation

15

Years of R&D

58

Worldwide Patents

23

US Patents

19

Peer Reviewed Publications

Empowering Next-Generation Diagnostics

The team at Xzōm is committed to delivering accessible, affordable, and accurate near-patient solutions for the detection of disease in its earliest stages, enabling faster intervention and improved outcomes.

Resources

Simultaneous Isolation of Circulating Nucleic Acids and EV-Associated Protein Biomarkers From Unprocessed Plasma Using an AC Electrokinetics-Based Platform

A Pilot Proof-of-Principle Analysis Demonstrating Dielectrophoresis (Dep) as a Glioblastoma Biomarker Platform